US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ipsen S.A.

29.34

0.0000

Volume:- -

Turnover:- -

Market Cap:9.69B

PE:13.44

High:29.34

Open:29.34

Low:29.34

Close:29.34

Loading ...

Overview Company News Filings

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen publishes its 2024 Universal Registration Document

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...

Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - Half year statement - 2024 12 31

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IPSEY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IPSEY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","market":"US","secType":"STK","nameCN":"Ipsen S.A.","latestPrice":29.34,"timestamp":1747835760000,"preClose":29.34,"halted":0,"volume":0,"delay":15,"floatShares":112371575,"shares":330397936,"eps":2.183055,"marketStatus":"Trading","change":0,"latestTime":"05-21 09:56:00 EDT Delay","open":29.34,"high":29.34,"low":29.34,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":2.183055,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1747857600000},"marketStatusCode":2,"adr":0,"adrRate":0.25,"exchange":"PINK LIMITED","adjPreClose":29.34,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","floatShares":112371575,"roa":"8.22%","roe":"8.93%","lyrEps":2.152613,"shares":330397936,"dividePrice":0.326,"high":29.34,"amplitude":0,"preClose":29.34,"low":29.34,"week52Low":25.11,"pbRate":"2.04","psRate":"2.39","week52High":34.06,"institutionHeld":0,"latestPrice":29.34,"eps":2.183055,"divideRate":0.011111,"volume":0,"delay":15,"ttmEps":2.183055,"open":29.34,"prevYearClose":28.97,"prevWeekClose":28.55,"prevMonthClose":28.2,"prevQuarterClose":29.2225,"fiveDayClose":28.48,"twentyDayClose":26.905,"sixtyDayClose":29.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPSEY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529647669","title":"Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2529647669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529647669?lang=en_us&edition=fundamental","pubTime":"2025-04-24 14:14","pubTimestamp":1745475240,"startTime":"0","endTime":"0","summary":"Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options. Patients treated with elafibranor versus placebo showed significant improvements in liver biochemical parameters, including alkaline phosphatase . Stabilization of non-invasive markers of liver fibrosis were observed in patients on elafibranor versus placebo. PARIS, FRANCE, 24 April 2025 Ipsen  will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver  congress as an oral presentation, on 10 May at 11.15 CET. For the first time data highlighting the potential of elafibranor in treating people living with primary sclerosing cholangitis  will be presented. PSC is a rare liver disease that currently has no approved treatment options.Patients on elafibranor also had stabilization i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-elafibranor-primary-sclerosing-cholangitis-061400283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","EC","BK4007","BK4201","LU0053671581.USD","BK4183","BK4599","ELF","LU1878469433.USD","LU1242518857.USD","PSC","BK4139","LU1242518931.SGD","ALT","LU0566484027.USD","LU0979878070.USD","IPSEF","PBC","IPSEY","BK4585","GGT","LU1559883803.SGD"],"gpt_icon":0},{"id":"2527235393","title":"Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2527235393","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527235393?lang=en_us&edition=fundamental","pubTime":"2025-04-16 12:57","pubTimestamp":1744779420,"startTime":"0","endTime":"0","summary":"Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.PARIS, FRANCE, 16 April 2025 - Ipsen , a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025.Ipsen is confirming financial guidance for full-year 2025:. Ipsen anticipates several key milestones across its portfolio in 2025, including:. The regulatory filing for tovorafenib was accepted by EMA for review in the European Union, marking an important step forward in the development of this potential treatment for pediatric low-grade glioma and reinforcing Ipsen’s commitment to innovation in rare and difficult-to-treat cancers.Ipsen announced on March 19th the successful completion of its inaugural Rated Public Bond of 500 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-delivers-strong-sales-first-045700973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEF","IPSEY"],"gpt_icon":0},{"id":"2527197677","title":"Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2527197677","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527197677?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:00","pubTimestamp":1744646400,"startTime":"0","endTime":"0","summary":"Monthly information relative to the total number of voting rights and shares composing the share capital. Total number of shares composing the share capital.  Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds .* Gross total= total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The Gross total is used as a basis for the calculation of threshold crossings.** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-march-2025-monthly-information-160000112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEF","IPSEY","BK4007"],"gpt_icon":0},{"id":"2526203810","title":"Ipsen publishes its 2024 Universal Registration Document","url":"https://stock-news.laohu8.com/highlight/detail?id=2526203810","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526203810?lang=en_us&edition=fundamental","pubTime":"2025-04-09 00:00","pubTimestamp":1744128000,"startTime":"0","endTime":"0","summary":"PARIS, FRANCE, 8 April 2025 - Ipsen  announced today the filing of its 2024 Universal Registration Document with the French Autorité des Marchés Financiers  on 7April 2025 and registered under the number D.25-0232.The document is available on ipsen.com and amf-france.org. Copies will also be available at Ipsen’s headquarters – 70 rue Balard, 75015 Paris, France.the Annual Financial Report including the Management Report, comprised especially of information relating to corporate governance and sustainability, as well as the parent company and consolidated financial statements,the information required for the share buy-back programme, as well as the Reports from the Statutory Auditors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-publishes-2024-universal-registration-160000065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UVV","IPSEF","IPSEY","BK4075","BK4007"],"gpt_icon":0},{"id":"2520108929","title":"Ipsen announces issuance of €500 million inaugural Rated Public Bond","url":"https://stock-news.laohu8.com/highlight/detail?id=2520108929","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520108929?lang=en_us&edition=fundamental","pubTime":"2025-03-19 14:00","pubTimestamp":1742364000,"startTime":"0","endTime":"0","summary":"Transaction follows Investment Grade ratings assignment from both S&P and Moody’s. PARIS, FRANCE, 19 March 2025 - Ipsen , a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of 500 million with a coupon of 3.875%, maturing in March 2032.“We are pleased with the outcome of this inaugural Rated Public Bond that reinforces and demonstrates investor’s confidence in Ipsen’s Investment Grade credit profile and long-term strategy,” said Aymeric Le Chatelier, Executive Vice President and Chief Financial Officer, Ipsen. “While we remain committed to a disciplined financial approach, this issuance will further support our ambition to deliver ongoing sustained growth, driven by our internal pipeline and external innovation.”This transaction is an important component of Ipsen’s refinancing plan which included the successful renewal of 1,5 billion syndicated Revolving Credit Facility completed earlier this month for a perio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-announces-issuance-500-million-060000965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","US12M.BOND","IPSEY","US7Y.BOND","US6M.BOND","IPSEF","US10Y.BOND","US5Y.BOND","BK4156","US3Y.BOND","US30Y.BOND","US2Y.BOND"],"gpt_icon":0},{"id":"2518030614","title":"Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins","url":"https://stock-news.laohu8.com/highlight/detail?id=2518030614","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518030614?lang=en_us&edition=fundamental","pubTime":"2025-03-12 14:28","pubTimestamp":1741760880,"startTime":"0","endTime":"0","summary":"PARIS, FRANCE, March 12th, 2025 - Ipsen , a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Executive Leadership Team  and report directly to Chief Executive Officer David Loew. In this newly created role, she will lead Ipsen’s global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic indications.Over the last 30 years in the neurotoxins market, Ipsen has established itself as one of the leading players in neurosciences, successfully driving research, clinical development and growth based on significant manufacturing know-how and capacity.This appointment reflects Ipsen’s continued investment in neurotoxin innovation, global expansion, and leadership in both therapeutic and aesthetic indications.About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in thre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-appoints-olivia-brown-executive-062800722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IPSEF","IPSEY"],"gpt_icon":0},{"id":"2517116002","title":"Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2517116002","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517116002?lang=en_us&edition=fundamental","pubTime":"2025-03-07 01:00","pubTimestamp":1741280400,"startTime":"0","endTime":"0","summary":"Monthly information relative to the total number of voting rights and shares composing the share capital. Total number of shares composing the share capital.  Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds .* Gross total= total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The Gross total is used as a basis for the calculation of threshold crossings.** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.Declaration relative to the total number of voting rights - February 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-february-2025-monthly-information-170000603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IPSEY","IPSEF"],"gpt_icon":0},{"id":"2511557630","title":"Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2511557630","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511557630?lang=en_us&edition=fundamental","pubTime":"2025-02-14 15:08","pubTimestamp":1739516905,"startTime":"0","endTime":"0","summary":"Total Sales Growth: 9.9% at constant exchange rates, exceeding EUR3.4 billion.Core Operating Income: EUR1.1 billion, a growth of 10.8%.Free Cash Flow: EUR774 million, an increase of 8.9%.Cabometyx Sales: Increased by 13.3% for the full year.ONIVYDE Sales: Grew 23.7% for the full year.Dysport Sales Growth: 9.2% for the full year.R&D Costs: Increased by 10.9%, exceeding 20% of sales.SG&A Costs: Increased by 3.3%, with a ratio to sales at 34.4%.Net Cash Position: EUR160 million at the end of December.Dividend Increase: From EUR1.2 to EUR1.4 per share.GuruFocus has detected 4 Warning Signs with IPSEF.Ipsen SA  reported a 9.9% increase in total sales for 2024, driven by strong performance in their ex-somatuline portfolio.Ipsen SA  has a strong balance sheet with no debt and EUR 2.3 billion available for external innovation, indicating financial stability and capacity for growth.Ipsen SA  faces increased competition and pricing pressure for Cabometyx in Europe and China, impacting sales grow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-sa-ipsef-full-2024-070825904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEF","IPSEY"],"gpt_icon":0},{"id":"2509092322","title":"Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2509092322","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509092322?lang=en_us&edition=fundamental","pubTime":"2025-02-07 01:00","pubTimestamp":1738861200,"startTime":"0","endTime":"0","summary":"Monthly information relative to the total number of voting rights and shares composing the share capital. Total number of shares composing the share capital.  Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds .* Gross total= total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The Gross total is used as a basis for the calculation of threshold crossings.** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-january-2025-monthly-information-170000935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IPSEY","IPSEF"],"gpt_icon":0},{"id":"2501780592","title":"Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2501780592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501780592?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:00","pubTimestamp":1736269200,"startTime":"0","endTime":"0","summary":"Monthly information relative to the total number of voting rights and shares composing the share capital. Total number of shares composing the share capital.  Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds .* Gross total= total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The Gross total is used as a basis for the calculation of threshold crossings.** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-december-2024-monthly-information-170000086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEF","BK4007","IPSEY"],"gpt_icon":0},{"id":"2501780591","title":"Ipsen - Half year statement - 2024 12 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2501780591","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501780591?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:00","pubTimestamp":1736269200,"startTime":"0","endTime":"0","summary":"Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF. Boulogne-Billancourt , January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account:. It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:. Between July 1st, 2024 and December 31st, 2024 have been executed:. Under the same period, the volumes traded represented:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-half-statement-2024-12-170000169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IPSEF","IPSEY"],"gpt_icon":0},{"id":"2490708352","title":"Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2490708352","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490708352?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"Monthly information relative to the total number of voting rights and shares composing the share capital. Total number of shares composing the share capital.  Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds .* Gross total= total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The Gross total is used as a basis for the calculation of threshold crossings.** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.Declaration relative to the total number of voting rights - November 2024","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-november-2024-monthly-information-170000654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEY","BK4007","IPSEF"],"gpt_icon":0},{"id":"2488954024","title":"Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488954024","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488954024?lang=en_us&edition=fundamental","pubTime":"2024-12-03 14:00","pubTimestamp":1733205600,"startTime":"0","endTime":"0","summary":"Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager  with first-in-class potential. BMX-502 is a bispecific antibody engaging MAIT cells, a subset of non-conventional T cells, and targeting the clinically validated tumor antigen GPC3 to kill cancer cells. PARIS, FRANCE; 03 December 2024 - Ipsen  and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated Invariant T cells  and targets the GPC3 tumor antigen, to kill cancer cells. GPC3 is a clinically validated target, highly expressed across several cancer types.1 MAIT cells are present throughout the body, highly enriched in many specific tissues of the body, particularly in mucosal and barrier tissues. BMX-502 offers a promising approach to treating tumors in these tissues.2,3","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ipsen-biomunex-announce-exclusive-global-060000962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEY","IPSEF","BK4007"],"gpt_icon":0},{"id":"2484690173","title":"Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2484690173","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484690173?lang=en_us&edition=fundamental","pubTime":"2024-11-18 14:00","pubTimestamp":1731909600,"startTime":"0","endTime":"0","summary":"Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024. “We know from our work with patient communities that receiving a diagnosis of PFIC and ALGS can be overwhelming in a patient or caregivers’ life. Disease symptoms like severe itch can have an impact on the whole family,” said Sandra Silvestri, EVP Chief Medical Officer, Ipsen. “Data suggesting Bylvay-treated patients experienced sustained efficacy, and which support the safety and tolerability profile seen in previous clinical trials, are important. Ipsen is committed to being the leader across rare cholestatic liver diseases and we are just getting started.”Beyond the clinically meaningful and sustained improvements seen in pruritus and sBA levels, height, weight and sleep increases were reported at 72 weeks in Bylvay-treated patients. Most adverse events in Bylvay-treated patients over the duration of the stu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bylvay-odevixibat-data-shows-sustained-060000611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4532","ALT","BK4505","BK4213","BK4233","IPSEY","BK4139","IPSEF","LU1878469433.USD","ALGS","AST","IBAT","LB","BK4079","FSV"],"gpt_icon":0},{"id":"2483306790","title":"Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306790","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483306790?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:00","pubTimestamp":1731686400,"startTime":"0","endTime":"0","summary":"Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024. Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. in October 2024. PARIS, FRANCE, 15 November 2024 Ipsen  announced today late-breaking data for Iqirvo  from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease  congress. The late-breaking presentations  report on biomarkers of cholestasis, stabilization of surrogate markers of liver fibrosis and moderate-to-severe pruritus data for up to three years in Iqirvo-treated patients. Additionally, exploratory endpoints in fatigue and sleep were evaluated using patient-reported outcomes tools.The impact of Iqirvo on fatigue and sleep were investigated as an","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iqirvo-elafibranor-data-shows-efficacy-160000898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4215","ESS","PBC","ML","BK4585","IPSEF","PRO","IPSEY","BK4023","BK4007","BK4588","BK4166"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPSEY\",params:#limit:5,,,undefined,":[{"date":"2024-07-25","symbol":"IPSEY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-05-31","symbol":"IPSEY","amount":0.235267,"announcedDate":"2024-05-20","type":"dividend","market":"US","newRecordDate":"2024-05-31","defaultRemindTime":1717162200000,"name":"Ipsen S.A.","recordDate":null,"payableDate":"2024-05-31","currency":"USD","dateTimestamp":1717128000000,"payDate":null},{"date":"2023-06-02","symbol":"IPSEY","amount":0.324045,"announcedDate":"2023-05-19","type":"dividend","market":"US","newRecordDate":"2023-06-05","defaultRemindTime":1685712600000,"name":"Ipsen S.A.","recordDate":"2023-06-27","payableDate":"2023-06-05","currency":"USD","dateTimestamp":1685678400000,"payDate":"2023-06-27"},{"market":"US","date":"2022-10-26","symbol":"IPSEY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1666756800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-07-28","symbol":"IPSEY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1658980800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPSEY\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-26","recordDate":"2015-05-28","paymentDate":"2015-07-06","value":0.1498,"currency":"USD"},{"executeDate":"2016-05-31","recordDate":"2016-06-02","paymentDate":"2016-07-13","value":0.177552,"currency":"USD"},{"executeDate":"2021-05-28","recordDate":"2021-06-01","paymentDate":"2021-06-09","value":0.275217,"currency":"USD"},{"executeDate":"2022-05-31","recordDate":"2022-06-01","paymentDate":"2022-06-09","value":0.315063,"currency":"USD"},{"executeDate":"2023-06-02","recordDate":"2023-06-05","paymentDate":"2023-06-27","value":0.324045,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPSEY\",market:\"US\",delay:false,,,undefined,":{}}}